Kiniksa generated total revenue of 202127000 dollars in Q4 2025, up from 122536000 dollars in Q4 2024, driven entirely by ARCALYST. The company reported net income of 14199000 dollars compared to a net loss in the prior year, while maintaining a strong cash position of 414074000 dollars.

Kiniksa Pharmaceuticals delivered a robust third quarter in 2025, with total revenue reaching $180.9 million, primarily fueled by ARCALYST net product revenue which grew 61% year-over-year. The company achieved a net income of $18.4 million, a significant improvement from a net loss in the prior year, and increased its cash, cash equivalents, and short-term investments to $352.1 million.

Kiniksa Pharmaceuticals reported strong first quarter 2025 financial results, driven by robust ARCALYST sales growth. Total revenue increased significantly year-over-year, leading to net income compared to a net loss in the prior year period. The company also provided an increased revenue guidance for ARCALYST for the full year 2025.

Kiniksa Pharmaceuticals reported strong commercial execution in 2024, resulting in 79% year-over-year ARCALYST sales growth to $417.0 million. The company is planning to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 and discontinue the development of abiprubart in Sjögren’s Disease.

Kiniksa Pharmaceuticals reported strong ARCALYST growth, driven by consistent execution and strategic investments. The company expects to remain cash flow positive on an annual basis while investing in commercialization and pipeline advancement.

Kiniksa Pharmaceuticals International, plc announced its financial results for the quarter ended June 30, 2024.

Kiniksa Pharmaceuticals reported strong first quarter 2024 results, driven by an 85% year-over-year increase in ARCALYST net product revenue, reaching $78.9 million. The company has raised its full-year ARCALYST net product revenue guidance to $370 - $390 million and plans to initiate a Phase 2b trial of abiprubart in Sjögren’s Disease in the second half of 2024. Kiniksa expects to remain cash flow positive on an annual basis.

Kiniksa reported strong Q4 2023 results driven by ARCALYST net product revenue growth. The company anticipates continued growth with ARCALYST in recurrent pericarditis and expects its commercial performance to contribute to a strong financial position.

Kiniksa Pharmaceuticals reported strong Q3 2023 financial results, highlighted by ARCALYST's net product revenue growth and progress in clinical trials for KPL-404. The company's cash reserves are expected to fund operations into at least 2027.

Kiniksa's Q2 2023 saw ARCALYST net product revenue reach $54.5 million. The company has increased its ARCALYST 2023 net product revenue guidance to $220 - $230 million. Cash reserves are now expected to fund operations into at least 2027.

Kiniksa Pharmaceuticals reported first quarter 2023 financial results, highlighted by ARCALYST® net product revenue of $42.7 million. The company increased ARCALYST full-year 2023 net product revenue guidance to $200 - $215 million. They are enrolling the final cohort of KPL-404 Phase 2 rheumatoid arthritis trial with data expected in 1H 2024. Cash reserves are expected to fund operations into at least 2026.

Kiniksa Pharmaceuticals reported fourth quarter and full-year 2022 financial results. The company is focused on increasing brand awareness of ARCALYST and pursuing collaborative study agreements for mavrilimumab. They are advancing the Phase 2 trial of KPL-404 in rheumatoid arthritis and expect data in the first half of 2024.

Kiniksa Pharmaceuticals reported strong ARCALYST performance in Q3 2022, driven by physician adoption, patient satisfaction, and payer access. The company is focused on positioning ARCALYST as the standard of care for recurrent pericarditis and is well-positioned to execute on synergistic growth opportunities across its portfolio.

Kiniksa Pharmaceuticals reported ARCALYST net revenue of $27.0 million for Q2 2022. The company anticipates $100 million in upfront and near-term proceeds from the vixarelimab global license agreement and expects cash reserves to fund operations into at least 2025.

Kiniksa Pharmaceuticals reported ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022.

Kiniksa announced ARCALYST collaboration achieved profitability in Q4 2021. They anticipate continued robust commercial execution and the further advancement of their clinical-stage pipeline in 2022. A strategic collaboration with Huadong Medicine was established to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific Region (excluding Japan).

Kiniksa Pharmaceuticals reported Q3 2021 financial results, highlighting ARCALYST's launch performance in recurrent pericarditis and progress in the clinical-stage pipeline, including mavrilimumab and vixarelimab.

Kiniksa Pharmaceuticals reported strong Q2 2021 results, driven by growth in ARCALYST revenue. The company is focused on advancing its pipeline and expanding ARCALYST's reach.

Kiniksa reported first quarter results, highlighting the FDA approval of ARCALYST for recurrent pericarditis and progress in their broader portfolio of immune-modulating assets, including mavrilimumab and KPL-404.

Kiniksa reported strong performance in 2020, driven by encouraging clinical data across its pipeline and regulatory designations for rilonacept, mavrilimumab, and vixarelimab. The company anticipates launching rilonacept in recurrent pericarditis in the first half of 2021, pending FDA approval, and expects data from clinical trials for KPL-404 and mavrilimumab in severe COVID-19 in the same period. With cash reserves of approximately $323 million, Kiniksa is well-capitalized.

Kiniksa continues to advance its pipeline, preparing for the potential commercial launch of rilonacept in recurrent pericarditis in the first half of 2021, pending FDA approval. The mavrilimumab Phase 2 trial in giant cell arteritis achieved statistical significance in primary and secondary efficacy endpoints. All cohorts have been dosed in the Phase 1 study of KPL-404, with data expected from the first cohorts this quarter.

Kiniksa had a successful first half of 2020, with positive results from studies of rilonacept and vixarelimab, as well as mavrilimumab data published in The Lancet Rheumatology. The company is planning to submit an sBLA to the FDA for rilonacept in recurrent pericarditis this year. Evaluations of mavrilimumab and vixarelimab are progressing, and data is expected in the fourth quarter from the mavrilimumab GCA trial and the KPL-404 program. Recent capital raises and financial discipline are expected to extend the company's cash runway into 2023.

Kiniksa reported first quarter 2020 financial results, highlighting the continued advancement of its clinical-stage pipeline despite the COVID-19 pandemic. The company's cash runway is projected to extend into the second half of 2021, and clinical timelines remain on track. Evaluation of mavrilimumab in COVID-19 pneumonia and hyperinflammation is progressing, with further clinical data expected from vixarelimab in the first half of 2020 and data from rilonacept, mavrilimumab, and KPL-404 in the second half of the year.

Kiniksa Pharmaceuticals reported their fourth quarter and full-year 2019 financial results, highlighting recent pipeline activity and year-end 2019 cash reserves of $233 million.